Author

A. J. Birkett

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Assay:proteomics· 3 Research Focus:drug response / drug discovery· 2 Organism:human· 2 Organism:rat· 2 Research Focus:cell type annotation· 1 Research Focus:host-pathogen & immune response· 1 Organism:mouse· 1

Frequent Co-Authors

A. M. Lias· 3 shared A. R. Noe· 3 shared B. G. Williams· 3 shared C. A. Long· 3 shared C. R. King· 3 shared H. Davies· 3 shared J. R. Barrett· 3 shared K. McHugh· 3 shared

Activity by Year

2024-2024 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersImmunology

A. M. Lias

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Analysis of the Diverse Antigenic Landscape of the Malaria Invasion Protein RH5 Identifies a Potent Vaccine-Induced Human Public Antibody Clonotype

J. R. Barrett, D. Pipini, N. D. Wright, A. J. R. Cooper, G. Gorini, D. Quinkert, A. M. Lias, H. Davies, C. Rigby, M. Aleshnick, B. G. Williams, W. J. Bradshaw, N. G. Paterson, T. Martinson, P. Kirtley, , S. J. Draper

The paper characterizes human antibodies against PfRH5, identifies key features of potent inhibitors, and demonstrates their prophylactic potential against malaria.

Cell · Sep 1, 2024Peer-reviewedImmunology

Development of an improved blood-stage malaria vaccine targeting the essential RH5-CyRPA-RIPR invasion complex

B. G. Williams, L. D. W. King, D. Pulido, D. Quinker, A. M. Lias, S. E. Silk, R. J. Ragotte, H. Davies, J. R. Barrett, K. McHugh, C. A. Rigby, D. G. W. Alanine, L. Barfod, M. W. Shea, L. A. Cowley, , S. J. Draper

This paper develops a combination malaria vaccine targeting the RCR-complex by fusing epitopes from RIPR to CyRPA, improving in vitro growth inhibition compared to RH5.1 alone.

Nature Communications · Jun 7, 2024Peer-reviewedImmunology

Preclinical Development of a Stabilized RH5 Virus-Like Particle Vaccine that Induces Improved Anti-Malarial Antibodies

L. D. W. King, D. Pulido, J. R. Barrett, H. Davies, D. Quinkert, A. M. Lias, S. E. Silk, D. J. Pattinson, A. Diouf, B. G. Williams, K. McHugh, A. Rodrigues, C. A. Rigby, V. Strazza, J. Suurbaar, , S. J. Draper

This paper develops a stabilized RH5 VLP vaccine that induces improved anti-malarial antibodies compared to a soluble protein vaccine in preclinical studies.

bioRxiv · Jan 4, 2024Immunology